Draft:Claudio Soto
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|  |
Claudio Soto | |
|---|---|
| Born | |
| Alma mater | University of Chile (PhD) |
| Known for | Protein misfolding cyclic amplification (PMCA), Seed Amplification Assays (SAA) |
| Awards | Robert A. Pritzker Prize for Leadership in Parkinson's Research (2024) |
| Scientific career | |
| Fields | Neurology, Biochemistry, Prion Biology |
| Institutions | University of Texas Health Science Center at Houston, University of Texas Medical Branch, Serono International |
Claudio Soto is an American-Chilean neuroscientist, academic, and biotechnology entrepreneur specializing in the molecular mechanisms of neurodegenerative diseases. He currently serves as the Huffington Distinguished University Chair, Professor of Neurology, and Director of the George and Cynthia Mitchell Center for Alzheimer's Disease and Related Brain Disorders at the University of Texas Health Science Center at Houston (UTHealth Houston).[1]
Soto is best known for inventing Protein misfolding cyclic amplification (PMCA), a revolutionary laboratory technology that mimics the amplification of DNA by PCR, but applies it instead to the replication of misfolded proteins.[2] This technique fundamentally proved the "protein-only hypothesis" of prion replication and has been adapted into ultra-sensitive diagnostics for Alzheimer's disease and Parkinson's disease.[3]
Education and Academic Career
[edit]Soto completed his undergraduate studies and earned his PhD in Biochemistry and Molecular Biology from the University of Chile.[1] Following his doctoral work, he completed postdoctoral training in structural biology and protein chemistry focused on central nervous system disorders.
Before his tenure at UTHealth Houston, Soto was the Chairman of Molecular Neurobiology at Serono International in Geneva, Switzerland. He later returned to academia as a professor at the University of Texas Medical Branch (UTMB) in Galveston, Texas, where he directed the Center for Protein Misfolding Diseases.[4]
Research and Innovations
[edit]Soto's research focuses primarily on the structural alterations of native proteins into neurotoxic beta-sheet rich aggregates, a hallmark of transmissible spongiform encephalopathies (TSEs) and other protein misfolding disorders.[3]
Protein Misfolding Cyclic Amplification (PMCA)
[edit]In 2001, Soto and his team conceptualized PMCA.[2] The process uses repeated cycles of incubation to let misfolded prions convert healthy proteins, followed by bursts of ultrasound (sonication) to break down the resulting large aggregates into smaller fragments, multiplying the infectious "seeds". Using this method, Soto's lab became among the first to successfully generate synthetic, highly infectious prions using pure, bacterially grown recombinant proteins, confirming that no viral genetic material is required to pass on prion diseases.
Seed Amplification Assays (SAA)
[edit]Soto transitioned PMCA technology into clinical diagnostics via Seed Amplification Assays (SAA). By testing cerebrospinal fluid and blood, his research enabled the detection of alpha-synuclein and amyloid-beta aggregates long before clinical cognitive or motor symptoms appear in Parkinson's and Alzheimer's patients.[4][5]
Entrepreneurship
[edit]To bridge academic discoveries with patient care, Soto co-founded Amprion Inc., a medical biotechnology corporation, where he acts as Chief Scientific Officer.[4] Under his leadership, the company's alpha-synuclein assay received FDA Breakthrough Device Designation for the early detection of Parkinson's disease pathology. He previously established Axonyx Inc., which focused on commercializing therapeutic pipelines for Alzheimer's disease.
Media Appearances and Public Lectures
[edit]Soto’s research into transmissible proteins and the boundaries of infectious disease has been featured across mainstream television, documentaries, and international scientific forums:
- Discovery Channel / Science Channel: He has appeared as an expert commentator in specials investigating the mysteries of Chronic wasting disease (CWD) and Bovine spongiform encephalopathy (Mad Cow Disease), explaining the potential risks of cross-species transmission.
- NPR and BBC World Service: Featured in radio and podcast segments discussing the paradigm shift of non-genetic infectious material and the future of diagnosing neurological decline through simple blood draws.
- Public Lectures: He delivered the keynote address at the International Prion Conference and has been an invited speaker at the World Economic Forum's global health panels to address the rising economic and social burden of neurodegenerative conditions in aging populations.
Awards and Honors
[edit]Soto has published more than 190 peer-reviewed articles across premier scientific journals including Nature, Science, Cell, and PNAS. He holds an exceptionally high H-index and his work has been cited over 38,000 times.
Key awards include:
- The Robert A. Pritzker Prize for Leadership in Parkinson's Research (2024), awarded by the Michael J. Fox Foundation for his paradigm-shifting contributions to early biomarker detection.[6]
- The Huffington Distinguished University Chair in Neurology.
References
[edit]- ^ a b "Claudio Soto, PhD - Neurology". McGovern Medical School. UTHealth Houston. Retrieved 2026-07-26.
- ^ a b Protein misfolding cyclic amplification
- ^ a b "Soto Lab Research". George and Cynthia Mitchell Center for Alzheimer's Disease. UTHealth Houston. Retrieved 2026-07-26.
- ^ a b c "Our Team: Claudio Soto, PhD". Ampriondx.com. Amprion Inc. Retrieved 2026-07-26.
- ^ Soto, Claudio (December 2025). "Seed amplification of MSA alpha-synuclein aggregates preserves the phenotypic characteristics of conformational strains". Nature Communications. Retrieved 2026-07-26.
- ^ "Neuroscientist Claudio Soto, PhD, Awarded 2024 Robert A. Pritzker Prize". Michaeljfox.org. The Michael J. Fox Foundation for Parkinson's Research. November 2024. Retrieved 2026-07-26.
Category:Living people Category:American neuroscientists Category:University of Chile alumni Category:University of Texas Health Science Center at Houston faculty Category:Biochemists
LLM-generated pages with certain obvious signs of being machine generated may be deleted without notice.
Instead, only summarize in your own words a range of independent, reliable, published sources that discuss the subject.
See the advice page on large language models for more information.